Near future
No Result
View All Result
February 4 2023
  • Home
  • Tech
  • Health
  • Environment
  • Energy
  • Inland solutions
  • Spazio
  • AI
  • concepts
  • H+
Understand, anticipate, improve the future.
CES2023 / Coronavirus / Russia-Ukraine
Near future
  • Home
  • Tech
  • Health
  • Environment
  • Energy
  • Inland solutions
  • Spazio
  • AI
  • concepts
  • H+

Understand, anticipate, improve the future.

No Result
View All Result
Medicine

A plant-based Covid vaccine is on the launch pad

Medicago and GSK have announced the start of phase 3 trials for their plant-based Covid vaccine.

READ THIS IN:

EN CN FR DE JA PT RU ES
Share31Pin8Tweet20SendShare5ShareShare4
March 21 2021
Gianluca RiccioGianluca Riccio
⚪ 3 minutes

Canadian biopharmaceutical company Medicago and pharmaceutical giant GlaxoSmithKline (GSK) are taking their plant-based Covid vaccine to phase 3 testing.

"We are delighted to take the significant step of launching the Phase 3 clinical trial at sites around the world," he said. Takashi Nagao, CEO and president of Medicago, in a Press release.

"This takes us one step closer to delivering a major new COVID-19 vaccine and contributing to the global fight against the pandemic together with our partner GSK ".

Plant-based Covid vaccines
Photo by Maria Chantal Rodriguez Nilsson on Unsplash

Another step forward

The first tests of the Covid vaccine have begun at the end of last fall, after the positive verification of its ability to cause the creation of antibodies that neutralize the virus.

The article continues after the related links

Approved the first vaccine against plague of bees

Covid, the bitter reality in the new WHO data: 15 million deaths in 2 years

In February, the American FDA granted the Covid vaccine a fast track of funds and bureaucracy given the emergency.

How the covid vaccine works

The Medicago vaccine uses both a different production form and a different target form.

That? Pfizer and Moderna's mRNA vaccines use the genetic code of the coronavirus spike protein as an antigen. The Sinovac vaccine and others use the inactivated virus.

Medicago's uses "Coronavirus-Like-Particles" (CoVLP) for its antigen. As the name suggests, these particles mimic viruses but without having the genetic material.

The immune system should respond to them as to the virus, even if they cannot replicate or cause an infection.

Plant-based Covid vaccine
Coronavirus-like particles

"Imposter" viruses

These mimic viruses are created in the leaves of N. benthamiana, Australian "relative" of tobacco.

Like most other Covid vaccines, the Medicago / GSK vaccine is also given in two doses.

The 3 phase

The phase 3 study will test the vaccine against a placebo, enrolling up to 30.000 people, starting with healthy adults between the ages of 18 and 65 before moving on to over 65s and people with comorbidities.

From Canada and the US, the study will then be extended to eight other countries, pending final approval.

It is not an isolated attempt: even British American Tobacco e iBio are working on plant-based Covid vaccines.

Medicago itself then tests a plant-based vaccine against seasonal flu, with good results in large clinical trials.

Hopefully, the "green line" will also open up for Covid vaccines.

Tags: CoronavirusGSKvaccines

To submit articles, disclose the results of a research or scientific discoveries write to the editorial staff

Most read in the week

  • 'AI lawyer' to assist client in a lawsuit: first time in the world

    1368 Shares
    Share 547 Tweet 342
  • I tested for you GPTZero, the weapon against the invasion of automatic texts.

    442 Shares
    Share 176 Tweet 110
  • Akio Toyoda has an idea: instead of new cars, we convert existing ones

    369 Shares
    Share 147 Tweet 92
  • Giant wind turbines like skyscrapers, a new study makes them possible

    315 Shares
    Share 126 Tweet 79
  • 27 jobs that will disappear within 50 years

    2836 Shares
    Share 1134 Tweet 709

Enter the Telegram channel of Futuroprossimo, click here. Or follow us on Instagram, Facebook, Twitter, Mastodon e LinkedIn.

The daily tomorrow.


Futuroprossimo.it provides news on the future of technology, science and innovation: if there is something that is about to arrive, here it has already arrived. FuturoProssimo is part of the network ForwardTo, studies and skills for future scenarios.

FacebookTwitterInstagramTelegramLinkedInMastodonPinterestTikTok
  • Environment
  • Architecture
  • Artificial intelligence
  • Gadgets
  • concepts
  • Design
  • Medicine
  • Spazio
  • Robotica
  • Work
  • Inland solutions
  • Energy
  • Edition Francaise
  • Deutsche Ausgabe
  • Japanese version
  • English Edition
  • Portuguese Edition
  • Русское издание
  • Spanish edition

Subscribe to our newsletter

  • The Editor
  • Advertising on FP

© 2022 Near future - Creative Commons License
This work is distributed under license Creative Commons Attribution 4.0 International.

No Result
View All Result
Understand, anticipate, improve the future.
  • Home
  • Tech
  • Health
  • Environment
  • Energy
  • Inland solutions
  • Spazio
  • AI
  • concepts
  • H+